BridgeBio is excited to announce the FDA approval of Attruby, a selective transthyretin stabilizer indicated for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Join us for an insightful 1-hour session with our panel of experts as they provide the latest information on this new option for managing patients with
ATTR-CM!
- Overview of Key Results From ATTRibute-CM
- Contemporary Trends in ATTR-CM
- Introduction to Attruby
- Discussion of Patient Cases
- Live Q&A
SELECT SAFETY INFORMATION
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Increase in serum creatinine and decrease in eGFR may occur within 4 weeks of starting Attruby and then stabilize. The laboratory changes were reversible after treatment discontinuation.
webinar dates
Tuesday, January 14, 2025
Presented by:
- Olakunle Akinboboye, MD, MPH, MBA, FACC, FAHA
- David G Wolinsky, MD, FACC, MASNC
- Richard F Wright , MD, FACC
6:00 – 7:00 PM ET
8:30 –9:30 PM ET
Meet the Experts
Tuesday, January 14, 2025
Olakunle Akinboboye, MD, MPH, MBA, FACC, FAHA
Clinical Professor of Cardiology
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
Medical Director
Queens Heart Institute/Laurelton Heart Specialists
New York, NY
Dr Akinboboye is a Clinical Professor of Cardiology at the Donald & Barbara Zucker School of Medicine at Hofstra/Northwell and the Medical Director at Queens Heart Institute/Laurelton Heart Specialists in New York City. He earned his medical degree from the University of Ibadan Medical School in Nigeria.
Dr Akinboboye subsequently completed an internship and residency in internal medicine and a fellowship in cardiology at Nassau County Medical Center and the State University of New York at Stony Brook. He is board certified in internal medicine, cardiovascular disease, nuclear cardiology, and
sleep medicine.
Dr Akinboboye is a fellow of the American College of Cardiology and American Heart Association and a member of the Society of Cardiovascular Computed Tomography. He is a prolific researcher and author, participating in more than a dozen clinical studies and publishing dozens of articles and abstracts.
Dr Akinboboye has received a humanitarian award from the University College Hospital Ibadan for his efforts to spread training and use of CPR techniques in Nigeria.
David G Wolinsky, MD, FACC, MASNC
Section Head Emeritus of Nuclear Cardiology, Medical Director
Director Emeritus of Cardiac Amyloidosis Center
Cleveland Clinic Florida
Weston, FL
Dr Wolinsky joined the staff at Cleveland Clinic Florida in 2011. He recently retired as Section Head of Nuclear Cardiology and Medical Director of Cardiac Rehabilitation. More recently, he developed the Cardiac Amyloidosis Center for which he was the Director. Under his leadership the clinic became the largest of its kind in South Florida.
Dr Wolinsky is a graduate of Columbia University where he received his undergraduate and medical degrees. He carried out his postgraduate training and was on staff at St. Luke’s Hospital in New York City for 7 years before joining Albany Associates in Cardiology in Albany, New York, where he worked as Director of the Nuclear Cardiology Program, which he founded, and also served as Director of the Heart Failure and Cardiac Rehabilitation and Wellness Programs.
Dr Wolinsky is a founding member of the American Society of Nuclear Cardiology. He was a member of the Board of Directors and the Executive Committee and served as President in 2015. Dr Wolinsky has been Chair of the Health Policy Committee since 2018 where he focuses on developing alliances that promote optimal utilization of noninvasive imaging to provide maximal value in the modern healthcare paradigm. He is Chair of the task force that has developed Refer Wisely, a joint initiative of the American Society of Nuclear Cardiology and the American College of Physicians to provide education regarding the appropriate use of diagnostic imaging with a specific focus on the appropriate use of myocardial perfusion imaging.
More recently, Dr Wolinsky focused much of his clinical work on cardiac amyloidosis. He established a multidisciplinary program for the management of amyloidosis that managed over 250 patients. He was involved in early diagnosis, nuclear imaging, and treatment of the disease. Dr Wolinsky developed the scintigraphic imaging program for cardiac amyloidosis and has helped multiple nuclear cardiology labs improve their testing. He has participated in multiple clinical trials and research projects aimed at a better understanding of cardiac amyloidosis.
Richard F Wright , MD, FACC
Chairman
Pacific Heart Institute
Cedars-Sinai, Santa Monica
Santa Monica, CA
Dr Wright earned his medical degree from Harvard Medical School and completed his medical residency and cardiology fellowships at Brigham and Women’s Hospital. Dr Wright served as Director of the Heart Institute at Saint John’s Health Center in Santa Monica and on the clinical faculty at UCLA. He is board certified in internal medicine, cardiovascular disease, and adult transthoracic and transesophageal echocardiography.
Dr Wright is a fellow of the American College of Cardiology and a member of the American Medical Association, American Society of Echocardiography, and Heart Failure Society of America. He is the Co-Director of the California Medicare Contractor Advisory Committee, Chair of the American College of Cardiology National Carrier Advisory Committee, and Cardiology Advisor for Medicare’s Relative Value Update Committee. Dr Wright is a co-author of the US heart failure guidelines and a past recipient of the Specialist of the Year Award from the American College of Cardiology, California.
INDICATION
Attruby™ (acoramidis) is indicated for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.
Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.
Use in Specific Populations
Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.
Please see full Prescribing Information for Attruby at Attruby.com/PI.
3160 Porter Drive, Suite 250, Palo Alto, CA 94304
© 2024 BridgeBio inc. All Rights Reserved.
Attruby is a trademark and the BridgeBio, Inc. corporate logo is a registered trademark of BridgeBio, Inc.
MAT–US-453 V2 12/2024